key: cord-0708691-a6y8k1a5
authors: Kow, Chia Siang; Hasan, Syed Shahzad
title: The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19
date: 2020-08-28
journal: Rev Esp Cardiol (Engl Ed)
DOI: 10.1016/j.rec.2020.08.009
sha: 7d458351b444e08f5e5f94508b05178f2544fed4
doc_id: 708691
cord_uid: a6y8k1a5

nan

No funding was received for the writing of this manuscript.

El uso de agentes antiplaquetarios para la tromboprofilaxis arterial en la COVID-19

To the Editor,

We read with interest the retrospective study reported by Rey et al. 1 to describe the clinical characteristics and outcomes of patients with novel coronavirus disease 2019 (COVID-19) who developed acute arterial thrombosis. Despite being a small-scale study (n = 87), there are a few clinical trends to be noted. Based on the reported findings, we observed that the proportion of COVID-19 patients with major cardiovascular risk factors who developed acute arterial thrombosis is higher than that of their non-COVID-19 counterparts. This finding hinted at the possibility that thromboinflammation plays a greater role for the development of arterial thrombosis in COVID-19 patients than traditional cardiovascular risk factors. In addition, the mortality rate of COVID-19 patients with arterial thrombosis was high (44.7%), which indicates a worse prognosis with COVID-19 patients.

Therefore, we would like to propose routine antiplatelet therapy (low-dose aspirin, clopidogrel, ticagrelor, prasugrel, ticlopidine, and dipyridamole) for arterial thromboprophylaxis in COVID-19 patients who are deemed at heightened risk for the development of acute arterial thrombosis. 

Arterial thrombotic complications in hospitalized patients with COVID-19

Lysine acetylsalicylate + glycine impairs coronavirus replication

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome